Medtronic announces US FDA clearance for a LigaSure instrument on Hugo
Source publication date
Summary
Medtronic said the US FDA cleared its LigaSure RAS Maryland instrument for the Hugo robotic-assisted surgery system. The addition brings vessel-sealing technology into the robotic workflow and expands available instruments in the US. The company said Hugo is cleared for US urologic procedures while broader general and gynecologic indications remain in development.
Editorial view
Editorial view: Surgical-robot competition depends on instruments, energy systems and authorized indications as well as the robot itself.
Evidence and limitations
FDA 510(k) record K261070 independently confirms a substantial-equivalence decision on September 15, 2026. This is not an independent evaluation of treatment outcomes. Medtronic is legally headquartered in Ireland; US identifies the regulatory and market event. Planned indication expansion is not completed clearance.